Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia-Reference-Cited by-同舟云学术

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

Published:2015-09-04 Issue:8 Volume:1 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Green Alexa S.¹²³⁴,Maciel Thiago T.⁵⁶⁷⁸,Hospital Marie-Anne¹²³,Yin Chae⁹,Mazed Fetta¹²³^ORCID,Townsend Elizabeth C.¹⁰^ORCID,Pilorge Sylvain¹²³¹¹,Lambert Mireille¹²³,Paubelle Etienne⁵⁶⁷⁸,Jacquel Arnaud¹¹,Zylbersztejn Florence⁵⁶⁷⁸,Decroocq Justine⁵⁶⁷⁸,Poulain Laury¹²³,Sujobert Pierre¹²³,Jacque Nathalie¹²³,Adam Kevin¹²³,So Jason C. C.⁹,Kosmider Olivier¹²³,Auberger Patrick¹¹,Hermine Olivier⁵⁶⁷⁸,Weinstock David M.¹⁰,Lacombe Catherine¹²³,Mayeux Patrick¹²³,Vanasse Gary J.¹²,Leung Anskar Y.⁹,Moura Ivan C.⁵⁶⁷⁸,Bouscary Didier¹²³,Tamburini Jerome¹²³

Affiliation:

1. Institut Cochin, Département Développement, Reproduction, Cancer, CNRS, UMR 8104, INSERM U1016, Paris 75014, France.

2. Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris 75005, France.

3. Equipe Labellisée, Ligue Nationale Contre le Cancer (LNCC), Paris 75013, France.

4. Department of Hematology, Charles Nicolle University Hospital, Rouen 76000, France.

5. INSERM UMR 1163, Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, Paris 75015, France.

6. Imagine Institute, Paris Descartes–Sorbonne Paris Cité University, Paris 75015, France.

7. CNRS ERL 8254, Paris 75015, France.

8. Laboratory of Excellence GR-Ex, Paris 75015 , France.

9. Division of Hematology, Department of Medicine, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

10. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston 02115, MA 02115, USA.

11. INSERM U1065/C3M Team 2, Cell Death Differentiation Inflammation and Cancer, Nice 06204, France.

12. Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Abstract

Synergy between FLT3 and Pim kinase inhibition in acute myeloid leukemia with FLT3-ITD mutation.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference54 articles.

1. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

2. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412;Weisberg E.;Cancer Cell,2002

3. Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

4. FLT3 as a therapeutic target in AML: Still challenging after all these years;Kindler T.;Blood,2010

5. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy;Critical Reviews in Oncology/Hematology;2024-09

2. Leukemic Stem Cells and Hematological Malignancies;International Journal of Molecular Sciences;2024-06-17

3. Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia;Biomarker Research;2024-06-10

4. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation;Cancer Research Communications;2024-02-16

5. Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia;Blood Advances;2023-12-15